Iridius, a compliance-by-design AI platform for regulated workflow execution, has raised $8.6 million in seed funding led by Chalfen Ventures, with participation from Osage Venture Partners, Accenture Ventures, and Rock Yard Ventures. Separately, Accenture has also made a strategic investment in Iridius through Accenture Ventures and announced a partnership to support life sciences organizations in scaling AI adoption with compliance, traceability, and auditability embedded at every stage.
Iridius builds enterprise AI infrastructure designed for highly regulated industries, with an initial focus on life sciences and pharmaceuticals. Its platform works by transforming regulatory standards and standard operating procedures into machine-readable, executable logic and embedding them directly into enterprise workflows, ensuring compliance is enforced, and audit evidence is generated continuously as systems operate, rather than applied after the fact. The platform includes a knowledge engine that converts regulatory standards into structured logic and an intelligent solution factory that orchestrates compliant workflows across the pharmaceutical value chain, spanning regulatory submissions, pharmacovigilance, and clinical and manufacturing operations.
The company was founded by veterans of Microsoft and AWS and has attracted an advisory board that includes industry leaders from Pfizer, Merck, Bayer, Novartis, Johnson & Johnson, Medtronic, Alexion, and Microsoft. Iridius has previously been named the winner of the ISG AI Startup Challenge in both Boston and a second market, and presented at the ISG AI Impact Summit.
The Accenture partnership will combine Accenture’s industry knowledge and delivery scale with Iridius’s regulatory and compliance AI capabilities, with the goal of helping life sciences clients move beyond isolated AI pilots and achieve enterprise-wide compliant AI transformation. Life sciences organizations face mounting pressure to accelerate the path from research to patient, while navigating complex global regulatory frameworks that demand rigorous standards for patient safety and data integrity.
KEY QUOTES:
“Together, we’re helping customers reimagine complex workflows with AI, turning it from a risk to manage into a trusted capability that strengthens compliance, enables innovation with confidence, and makes compliance a strategic advantage.”
Mike Kropp, Co-Founder and CEO, Iridius
“Our investment in Iridius is about giving life sciences organizations the ability to innovate without hesitation. By embedding compliance into the core of AI, we’re helping accelerate clinical development, improve decision-making, and bring therapies to patients faster.”
Ray Pressburger, Global Life Sciences Lead, Accenture
